Expert Insights into the Management of Newly Diagnosed Ph+ ALL

Expert physicians delve into the latest data and strategies for managing newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

EP. 1: Ph+ ALL Management Updates: Expert Insights

August 29th 2023

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

EP. 2: Advancing the Treatment Landscape in Philadelphia-Positive ALL

August 29th 2023

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.

EP. 3: Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

September 5th 2023

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

EP. 4: PhALLCON Trial: Safety and Efficacy of Ponatinib in Philadelphia-positive ALL

September 5th 2023

Expert hematologist-oncologists consider how the PhALLCON trial elucidates the safety of ponatinib in Ph+ ALL, highlighting comparable toxicity rates and favorable efficacy endpoints.

EP. 5: Optimizing Real-World Ponatinib Use in Ph+ ALL: Treatment Considerations

September 12th 2023

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS.

EP. 6: Advances in Ph+ ALL: Evolving Therapies and Future Strategies

September 12th 2023

Hagop M. Kantarjian, MD, and Bijal D. Shah, MD, MS, delve into upcoming strategies for handling Philadelphia-chromosome positive acute lymphoblastic leukemia, considering recent breakthroughs.